Studying good cholesterol function in type 1 diabetes with kidney disease
Compares blood and urine samples in adults with type 1 diabetes and kidney disease.
Plain-language title generated from the registry record
Registry title: Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
Key facts
- Where
- Dijon, FranceSee the site
Where in France
- Chu Dijon BourogneDijon, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire Dijon
- Trial code
- NCT03512132
- Record updated
- 30 October 2026
- Original description
A number of arguments suggest that the deterioration in high density lipoproteins (HDL) functioning may worsen with the development of nephropathy during type 1 diabetes (T1D).Read full original descriptionShow less
Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
A number of arguments suggest that the deterioration in high density lipoproteins (HDL) functioning may worsen with the development of nephropathy during type 1 diabetes (T1D).
The objective of this study will be to investigate to what extent nephropathy in T1D patients in the microalbuminuria and macroalbuminuria stages, compared to T1D patients without nephropathy, is associated with an alteration in HDL functionality and changes in HDL size and composition (lipids with detailed study of phosphates and sphingolipids, main lipoproteins, inflammatory markers).
Inclusion: age > 18 years; a person who has given oral consent; Non-diabetics; Fasting plasma glucose < 6.10 mmol/L (1.1 g/L); Triglyceridemia < 1.7 mmol/L (1.5 g/l); HDL-C concentration > 1.30 mmol/L (for women and 1.03 mmol/L for men); Glomerular filtration flow rate > 90 mL/min/1.73m2 (These thresholds correspond to the standard thresholds for these parameters); age > 18 years; a person who has given oral consent; Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l); HbA1c between 6 and 9%; normal albuminuria (albumin/creatinine ratio < 2.5 mg/mmol in men and < 3.5 in women); glomerular filtration rate > 90 mL/min/1.73m2; age > 18 years; a person who has given oral consent; Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l); HbA1c between 6 and 9%; Microalbuminuria (albumin/creatinine ratio > 2.5 mg/mmol in men and > 3.5 in women, and < 30 mg/mmol); glomerular filtration rate > 90 mL/min/1.73m2; age > 18 years; a person who has given oral consent; Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l); HbA1c between 6 and 9%; Macroalbuminuria (albumin/creatinine ratio > 30 mg/mmol); glomerular filtration rate > 45 mL/min/1.73m2.
Exclusion: Drugs interfering with lipid metabolism outside insulin for DT1 : hypolipidemic (only for patients included in the DT1-micro group), corticosteroid, estroprogestogens, retinoic acid, antiproteases; Protected adult; Patient not affiliated to a social security scheme; Pregnant or breastfeeding woman; BMI > 30 kg/m2.